Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0OQAEX
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
LNCB74
|
|||||
| Synonyms |
LNCB74; LCB41A
Click to Show/Hide
|
|||||
| Organization |
NextCure (Originator);LCB
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
|
|
||||||
| Antibody Name |
Anti-B7-H4 IgG1k mAb
|
Antibody Info | ||||
| Antigen Name |
V-set domain-containing T-cell activation inhibitor 1 (VTCN1)
|
Antigen Info | ||||
| Payload Name |
MMAE
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
β-glucuronide linker
|
Linker Info | ||||
| Conjugate Type |
Enzymatic Catalysis
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Biliary tract cancer |
1 Trials
|
||||||||
| Breast cancer |
1 Trials
|
||||||||
| Endometrial cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Ovarian cancer |
1 Trials
|
||||||||
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Inclusion: Adults (≥18) with advanced/metastatic solid tumors (RECIST 1.1-measurable), ECOG 0-1, life expectancy ≥12 weeks, adequate organ function, willingness for biopsies, and contraception compliance. Exclusion: Prior MMAE-ADC therapy, platinum-refractory disease, active CNS metastases, Grade≥2 neuropathy/corneal disease, uncontrolled infections (HIV/HBV/HCV), recent anticancer therapies (chemotherapy within 2 weeks, antibodies within 4 weeks, radiotherapy within 2-4 weeks), immunosuppression, or significant comorbidities (cardiovascular, interstitial lung disease, bowel obstruction). Pregnancy, breastfeeding, or unresolved toxicities (>Grade 1) also exclude participation.
Click to Show/Hide
|
||||
| Administration Dosage |
LNCB74 is an antibody drug conjugate being evaluated as a potential treatment for participants with advanced solid tumors. Participants will receive LNCB74 into the vein (IV; intravenously) in 21-day dosing cycles. Participants will continue treatment in the absence of unacceptable toxicities and unequivocal disease progression.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06774963 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors | ||||
| Primary Endpoint |
The study aims to evaluate the safety and tolerability of LNCB74 over 24 months, assessing incidence of AEs, SAEs, DLTs, discontinuations, and deaths per NCI CTCAE v5.0. Additionally, it seeks to determine the RP2D (based on MTD, MAD, and cumulative safety/PK data) and define the maximum tolerated/feasible dose.
|
||||
| Other Endpoint |
Efficacy measures include ORR, DOR, DCR, and PFS at 6/24 months (per RECIST 1.1), alongside correlations between B7-H4 expression (via central IHC) and clinical outcomes (ORR, DOR, DCR, PFS). Pharmacokinetics (Tmax, AUC, T1/2, Cmax) are evaluated across multiple cycles (Days 1-15, Cycles 1-9). Immunogenicity (anti-drug antibodies) is monitored for 24 months.
Click to Show/Hide
|
||||